Natural Product (NP) Details
General Information of the NP (ID: NP5775) | |||||
---|---|---|---|---|---|
Name |
Cyclopamine
|
||||
Synonyms |
CYCLOPAMINE; 11-Deoxojervine; 4449-51-8; 11-Deoxyjervine; UNII-ZH658AJ192; CHEBI:4021; CHEMBL254129; ZH658AJ192; (2'R,3S,3'R,3a'S,6aS,6bS,6'S,7a'R,11aS,11bR)-3',6',10,11b-tetramethyl-1,2,3,3a',4,4',5',6,6a,6b,6',7,7',7a',8,11,11a,11b-octadecahydro-3'H-spiro[benzo[a]fluorene-9,2'-furo[3,2-b]pyridin]-3-ol; Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)- (9CI); (3beta,22S,23R)-17,23-epoxyveratraman-3-ol; HSDB 3505; CY8; [3H]-Cyclopamine; Jervine, 11-deoxo-; DSSTox_CID_23709; DSSTox_RID_80067; DSSTox_GSID_43709; SCHEMBL29153; BSPBio_001032; MLS006010945; Veratraman-3-ol, 17,23-epoxy-, (3beta,23beta)-; Jervine, 11-deoxo- (7CI); DTXSID6043709; GTPL10328; AOB1606; EX-A952; BCPP000271; HMS1792D13; HMS1990D13; HMS3403D13; ZINC4098868; Tox21_300632; BDBM50232973; MFCD01735266; NSC734950; s1146; AKOS024456709; BCP9000568; CCG-208181; CS-0633; NSC 734950; NSC-734950; NCGC00163474-03; NCGC00163474-04; NCGC00163474-07; NCGC00254431-01; HY-17024; SMR001822854; CAS-4449-51-8; (3beta23R)-17,23-Epoxyveratraman-3-ol; AB0007896; 6832-EP2316832A1; 6832-EP2316833A1; C10798; W-5421; SR-05000002357; Veratraman-3-ol,23-epoxy-, (3-beta,23-beta)-; Q-200904; Q3271319; SR-05000002357-2; BRD-K58938839-001-03-8; (3alpha,8alpha,14beta,22S,23R)-17,23-epoxyveratraman-3-ol; Veratraman-3-ol, 17,23-epoxy-, (3-beta,23-beta)- (9CI); (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-Octadecahydro-3',6',10,11b-tetramethylspiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol; 11051-96-0; Spiro(9H-benzo(a)fluorene-9,2-b)pyridin)-3-o l, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octa deca hydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-
Click to Show/Hide
|
||||
Species Origin | Veratrum californicum ... | Click to Show/Hide | |||
Veratrum californicum | |||||
Disease | Prostate hyperplasia [ICD-11: GA90] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C27H41NO2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1
|
||||
InChI |
1S/C27H41NO2/c1-15-11-24-25(28-14-15)17(3)27(30-24)10-8-20-21-6-5-18-12-19(29)7-9-26(18,4)23(21)13-22(20)16(27)2/h5,15,17,19-21,23-25,28-29H,6-14H2,1-4H3/t15-,17+,19-,20-,21-,23-,24+,25-,26-,27-/m0/s1
|
||||
InChIKey |
QASFUMOKHFSJGL-LAFRSMQTSA-N
|
||||
CAS Number |
CAS 4449-51-8
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Tamoxifen | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of cyclopamine and tamoxifen promotes survival and migration of mcf-7 breast cancer cells--interaction of hedgehog-gli and estrogen receptor signaling pathways. | |||||
Erlotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | PROM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Cells derived from glioblastoma patients | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
Synergic efficiency for erlotinib-cyclopamine association and provide a suitable in vitro model to explore drug combinations on GBM cells. | |||||
Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combined cyclopamine and gefitinib were more effective at suppressing the invasiveness of PC3 cells through matrigel in vitro as the drugs alone. | |||||
Docetaxel + Gefitinib | Click to Show/Hide the Molecular Data of This Drug | |||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Combined use of inhibitors of EGF-EGFR and hedgehog signaling with docetaxel could represent a more promising strategy for treatment in patients with metastatic and androgen-independent prostate cancer. | |||||
β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of TMZ with micellarized Cyp is a promising strategy for exerting different functions of drugs for tumor treatment. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
Experimental
Result(s) |
Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. | |||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | SW1990 | CVCL_1723 | Pancreatic adenocarcinoma | Homo sapiens | ||
CFPAC-1 | CVCL_1119 | Cystic fibrosis | Homo sapiens | |||
Experimental
Result(s) |
Gemcitabine-resistant pancreatic cancer cells highly express CSCs markers and some of the HH members, and inhibition of HH by cyclopamine is an effective method of reversing gemcitabine resistance in pancreatic cancer. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Smoothened homolog (SMO) | Molecule Info | [9] | |
KEGG Pathway | Hedgehog signaling pathway | Click to Show/Hide | ||
2 | Pathways in cancer | |||
3 | Proteoglycans in cancer | |||
4 | Basal cell carcinoma | |||
Panther Pathway | Hedgehog signaling pathway | Click to Show/Hide | ||
Pathway Interaction Database | Signaling events mediated by the Hedgehog family | Click to Show/Hide | ||
2 | Hedgehog signaling events mediated by Gli proteins | |||
Reactome | Class B/2 (Secretin family receptors) | Click to Show/Hide | ||
2 | Hedgehog 'off' state | |||
3 | Activation of SMO | |||
WikiPathways | Hedgehog Signaling Pathway | Click to Show/Hide | ||
2 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
3 | Hair Follicle Development: Induction (Part 1 of 3) | |||
4 | Integrated Pancreatic Cancer Pathway | |||
5 | GPCR ligand binding | |||
6 | GPCRs, Other |




